Role of carfilzomib in the treatment of multiple myeloma

References

• Waxman AJ, Mink PJ, Devesa SS et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116(25), 5501–5506 (2010).
   PubMed Web of Science ®Google Scholar
• Kastritis E, Zervas K, Symeonidis A et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 23(6), 1152–1157 (2009).
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5), 2516–2520 (2008).
   PubMed Web of Science ®Google Scholar
• Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem. Biol. 2(8), 503–508 (1995).
   PubMed Web of Science ®Google Scholar
• Elliot PJ, Adams J. Recent advances in understanding proteasome function. Curr. Opin. Drug Discov. Devel. 2(5), 484–490 (1999).
   PubMedGoogle Scholar
• Orlowski M, Wilk S. Catalytic activities of the 20S proteasome, a multicatalytic proteinase complex. Arch. Biochem. Biophys. 383(1), 1–16 (2000).
   PubMed Web of Science ®Google Scholar
• Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem. Soc. Trans. 35(Pt 1), 12–17 (2007).
   PubMed Web of Science ®Google Scholar
• Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl Acad. Sci. USA 100(17), 9946–9951 (2003).
   PubMed Web of Science ®Google Scholar
• Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107(12), 4907–4916 (2006).
   PubMed Web of Science ®Google Scholar
• Dong H, Chen L, Chen X et al. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk. Lymphoma 50(6), 974–984 (2009).
   PubMed Web of Science ®Google Scholar
• Qin JZ, Ziffra J, Stennett L et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 65(14), 6282–6293 (2005).
   PubMed Web of Science ®Google Scholar
• Gomez-Bougie P, Wuillème-Toumi S, Ménoret E et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 67(11), 5418–5424 (2007).
   PubMed Web of Science ®Google Scholar
• Fennell DA, Chacko A, Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27(9), 1189–1197 (2008).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Akiyama M et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101(4), 1530–1534 (2003).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61(7), 3071–3076 (2001).
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl Acad. Sci. USA 99(22), 14374–14379 (2002).
   PubMed Web of Science ®Google Scholar
• Podar K, Gouill SL, Zhang J et al. A pivotal role for Mcl-1 in bortezomib-induced apoptosis. Oncogene 27(6), 721–731 (2008).
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 17(10), 2036–2045 (2003).
   PubMed Web of Science ®Google Scholar
• Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Proteasome inhibitor therapy in multiple myeloma. Mol. Cancer Ther. 4(4), 686–692 (2005).
   PubMed Web of Science ®Google Scholar
• Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR. NF-κB in the pathogenesis and treatment of multiple myeloma. Curr. Opin. Hematol. 15(4), 391–399 (2008).
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4(5), 349–360 (2004).
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 12(2), 131–144 (2007).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P et al. NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem. 277(19), 16639–16647 (2002).
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades N, Poulaki V et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21(37), 5673–5683 (2002).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26), 2609–2617 (2003).
   PubMed Web of Science ®Google Scholar
• Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8(6), 508–513 (2003).
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK et al.; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359(9), 906–917 (2008).
   PubMed Web of Science ®Google Scholar
• Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest. 22(2), 304–311 (2004).
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Res. 59(11), 2615–2622 (1999).
   PubMed Web of Science ®Google Scholar
• Genin E, Reboud-Ravaux M, Vidal J. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. Curr. Top. Med. Chem. 10(3), 232–256 (2010).
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Stinchcombe TE, Mitchell BS et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20(22), 4420–4427 (2002).
   PubMed Web of Science ®Google Scholar
• Velcade prescribing information. Millennium Pharmaceuticals, Cambridge, MA. 2009.
   Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ et al.; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26(1), 149–157 (2012).
   PubMed Web of Science ®Google Scholar
• Rückrich T, Kraus M, Gogel J et al. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 23(6), 1098–1105 (2009).
   PubMed Web of Science ®Google Scholar
• Lü S, Yang J, Song X et al. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J. Pharmacol. Exp. Ther. 326(2), 423–431 (2008).
   PubMed Web of Science ®Google Scholar
• Oerlemans R, Franke NE, Assaraf YG et al. Molecular basis of bortezomib resistance: proteasome subunit b5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112(6), 2489–2499 (2008).
   PubMed Web of Science ®Google Scholar
• Ri M, Iida S, Nakashima T et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24(8), 1506–1512 (2010).
   PubMed Web of Science ®Google Scholar
• Franke NE, Niewerth D, Assaraf YG et al. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 26(4), 757–768 (2012)
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr, Qu P, Usmani S et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 118(13), 3512–3524 (2011).
   PubMed Web of Science ®Google Scholar
• Chauhan D, Li G, Shringarpure R et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 63(19), 6174–6177 (2003).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bradner JE, Wong J et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic anti-tumor activity in multiple myeloma. Proc. Natl Acad. Sci. USA 102(24), 8567–8572 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR. Characterization of bortezomib-adapted I-45 mesothelioma cells. Mol. Cancer 9, 110 (2010).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Delforge M, Beksac M et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26(4), 595–608 (2012).
   PubMed Web of Science ®Google Scholar
• Delforge M, Blade J, Dimopoulos MA et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 11(11), 1086–1095 (2011).
   Web of Science ®Google Scholar
• Terpos E, Cibeira MT, Blade J, Ludwig H. Management of complications in multiple myeloma. Semin. Hematol. 46(2), 176–189 (2009).
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk. Lymphoma 51(7), 1178–1187 (2010).
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, Phase 3, non-inferiority study. Lancet Oncol. 12(5), 431–440 (2011).
   PubMed Web of Science ®Google Scholar
• Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl Acad. Sci. USA 96(18), 10403–10408 (1999).
   PubMed Web of Science ®Google Scholar
• Arastu-Kapur S, Anderl JL, Kraus M et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin. Cancer Res. 17(9), 2734–2743 (2011).
   PubMed Web of Science ®Google Scholar
• Demo stable disease, Kirk CJ, Aujay MA et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67(13), 6383–6391 (2007).
   PubMed Web of Science ®Google Scholar
• Trudel S, Lee S, Kirk CJ et al. Inhibition of the proteasome in bone marrow-derived CD138+ tumor cells following carfilzomib administration in relapsed or refractory myeloma patients. Presented at: 51st ASH Annual Meeting. New Orleans, LA, USA, 5–8 December 2009 (Abstract 1845).
   Google Scholar
• Suzuki E, Demo S, Arastu-Kapur S, Kirk CJ, Bennett MK. Bortezomib-resistant cell lines have increased proteasome levels but remain sensitive to carfilzomib. Presented at: 51st ASH Annual Meeting. New Orleans, LA, USA, 5–8 December 2009 (Abstract 2852).
   Google Scholar
• Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10(4), 307–317 (2011).
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110(9), 3281–3290 (2007).
   PubMed Web of Science ®Google Scholar
• Yang J, Wang Z, Fang Y et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab. Dispos. 39(10), 1873–1882 (2011).
   PubMed Web of Science ®Google Scholar
• Hemeryck A, Geerts R, Monbaliu J et al. Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. Cancer Chemother. Pharmacol. 60(6), 777–787 (2007).
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Stewart AK, Vallone M et al. A Phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res. 15(22), 7085–7091 (2009).
   PubMed Web of Science ®Google Scholar
• Alsina M, Trudel S, Vallone M, Molineaux C, Kunkel L, Goy A. Phase 1 single agent anti-tumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Presented at: The American Society of Hematology 49th Annual Meeting. New Orleans, LA, USA 8–11 December 2007 (Abstract 411).
   Google Scholar
• Jagannath S, Vij R, Stewart K et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, Phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J. Clin. Oncol. 27(15S, Suppl.) (2009) (Abstract 8504).
   Google Scholar
• Siegel Dstable disease, Martin T, Wang M et al. PX-171-003-A1, an open-label, single-arm, Phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 8027).
   Google Scholar
• Stewart AK, Kaufman JL, Jakubowiak AJ et al. The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): updated results from the PX-171-004 study. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 8026).
   Google Scholar
• Vij R, Kaufman JL, Jakubowiak AJ et al. Final results from the bortezomib-naive group of PX-171-004, a Phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MM. Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10–13 December 2011 (Abstract 813).
   Google Scholar
• Siegel D, Wang L, Orlowski RZ et al. PX-171-004, an ongoing open-label, Phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10–13 December 2011 (Abstract 303).
   Google Scholar
• Badros AZ, Vij R, Martin T et al. Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency. J. Clin. Oncol. 28(15S) (2010) (Abstract 8128).
   Google Scholar
• Squifflet P, Michiels S, Siegel DS, Vij R, Ro S, Buyse ME. Multivariate modelling reveals evidence of a dose-response relationship in Phase 2 studies of single-agent carfilzomib. Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10–13 December 2011 (Abstract 1877).
   Google Scholar
• Rosen PJ, Gordon M, Lee PN et al. Phase II results of study PX-171-007: a Phase Ib/II study of carfilzomib (CFZ), a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors. J. Clin. Oncol. 27(15S) (2009) (Abstract 3515).
   Google Scholar
• Papadopoulos KP, Lee P, Singhal S et al. A Phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56mg/m2 expansion cohort of PX-171-007. Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10–13 December 2011 (Abstract 2930).
   Google Scholar
• Niesvizky R, Bensinger W, Vallone M, Gutierrez A, Kunkel L. PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): preliminary results. J. Clin. Oncol. 27(15S) (2009) (Abstract 8541).
   Google Scholar
• Wang M, Bensinger W, Martin T et al. Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). J. Clin. Oncol. 29 (Suppl.) (2011) (Abstract 8025).
   Google Scholar
• Jakubowiak AJ, Dytfeld D, Jagannath S et al. Final Results of a frontline Phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10–13 December 2011.
   Google Scholar
• Moreau P, Palumbo AP, Stewart AK et al. A randomized, multicenter, Phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM). J. Clin. Oncol. 29 (Suppl.) (2011) (Abstract TPS225).
   Google Scholar
• Wang L, Siegel DS, Jakubowiak AJ et al. The speed of response to single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma: an exploratory analysis of results from 2 multicenter Phase 2 clinical trials. Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10–13 December 2011 (Abstract 3969).
   Google Scholar
• Jakubowiak AJ, Siegel DS, Singhal S et al. Unfavorable cytogenetic characteristics do not adversely impact response rates in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib on the 003 (A1) study. Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10–13 December 2011 (Abstract 1875).
   Google Scholar
• Singhal S, Siegel DS, Martin T et al. Integrated safety from Phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10–13 December 2011 (Abstract 1876).
   Google Scholar
• Paramore A, Frantz S. Bortezomib. Nat. Rev. Drug Discov. 2(8), 611–612 (2003).
   PubMed Web of Science ®Google Scholar